Baldassarre G, Bianco C, Tortora G, Ruggiero A, Moasser M, Dmitrovsky E, Bianco A R, Ciardiello F
Cattedra di Oncologia Medica, Università degli Studi di Napoli Federico II, Naples, Italy.
Int J Cancer. 1996 May 16;66(4):538-43. doi: 10.1002/(SICI)1097-0215(19960516)66:4<538::AID-IJC19>3.0.CO;2-3.
CRIPTO is a member of the epidermal growth factor (EGF) gene family originally isolated from undifferentiated human NTERA2 clone D1 (NT2D1) multipotent embryonal carcinoma cells. Retinoic acid (RA) treatment of NT2D1 cells leads to a neuronal differentiation program and to concomitant loss of CRIPTO mRNA expression. To assess the role of CRIPTO in the control of NT2D1 cell growth or differentiation, these cells were treated with 3 anti-sense oligodeoxynucleotides complementary to the 5' end of the human CRIPTO mRNA. A dose-dependent inhibition of monolayer and soft agar growth was observed with each of these CRIPTO anti-sense oligodeoxynucleotides but not with a control oligodeoxynucleotide of random sequence or with the 3 corresponding CRIPTO sense oligodeoxynucleotides. In addition, NT2D1 cells were transfected with a recombinant expression vector containing a 918-bp coding fragment of the human CRIPTO cDNA in the 3' to 5' orientation. NT2D1 CRIPTO anti-sense transfectants exhibited a significantly reduced endogenous CRIPTO mRNA and protein, a 4- to 5-fold decrease in growth rate in monolayer and a 50-70% reduction in cloning efficiency in soft agar as compared with NT2D1 parental cells or with NT2D1 cells transfected with a plasmid containing the neomycin-resistance gene alone (NT2D1 neo cells). Finally, we examined the expression of immunophenotypic markers that are modulated during the differentiation of NT2D1 cells following RA treatment. The globoseries stage-specific embryonic antigen-3 recognized by the monoclonal antibody (MAb) SSEA-3 was expressed in 60% of undifferentiated parental NT2D1 or NT2D1 neo cells and in only 20% of NT2D1 CRIPTO anti-sense transfectants, whereas it was down-regulated in all cell lines following RA treatment. A neuroectodermal antigen recognized by the A2B5 MAb, which was not expressed in parental NT2D1, in NT2D1 neo or in CRIPTO anti-sense NT2D1 cells, was induced by RA treatment in all cell lines. Taken together, our results show that inhibition of endogenous CRIPTO expression in human embryonal carcinoma cells interferes with both transformation and differentiation.
CRIPTO是表皮生长因子(EGF)基因家族的成员,最初从未分化的人NTERA2克隆D1(NT2D1)多能胚胎癌细胞中分离得到。用视黄酸(RA)处理NT2D1细胞会导致神经元分化程序,并伴随CRIPTO mRNA表达的丧失。为了评估CRIPTO在控制NT2D1细胞生长或分化中的作用,用3种与人CRIPTO mRNA 5'端互补的反义寡脱氧核苷酸处理这些细胞。这些CRIPTO反义寡脱氧核苷酸中的每一种都观察到对单层和软琼脂生长的剂量依赖性抑制,但随机序列的对照寡脱氧核苷酸或3种相应的CRIPTO正义寡脱氧核苷酸则没有。此外,用一个重组表达载体转染NT2D1细胞,该载体含有3'至5'方向的人CRIPTO cDNA的918bp编码片段。与NT2D1亲代细胞或仅转染了含有新霉素抗性基因的质粒的NT2D1细胞(NT2D1 neo细胞)相比,NT2D1 CRIPTO反义转染子的内源性CRIPTO mRNA和蛋白质显著减少,单层生长速率降低4至5倍,软琼脂中的克隆效率降低50 - 70%。最后,我们检测了RA处理后NT2D1细胞分化过程中被调节的免疫表型标志物的表达。单克隆抗体(MAb)SSEA - 3识别的球系列阶段特异性胚胎抗原 - 3在60%的未分化亲代NT2D1或NT2D1 neo细胞中表达,而在仅20%的NT2D1 CRIPTO反义转染子中表达,而在RA处理后所有细胞系中其表达均下调。A2B5 MAb识别的一种神经外胚层抗原,在亲代NT2D1、NT2D1 neo或CRIPTO反义NT2D1细胞中不表达,但在所有细胞系中经RA处理后被诱导表达。综上所述,我们的结果表明,抑制人胚胎癌细胞中内源性CRIPTO的表达会干扰转化和分化。